Pulmatrix, Inc. (PULM) Financial Statements (2026 and earlier)

Company Profile

Business Address 945 CONCORD STREET
FRAMINGHAM, MA 01701
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,0884,7945,8257,7089,52110,782
Cash and cash equivalent4,0884,7945,8257,7089,52110,782
Restricted cash and investments      
Receivables    16 23
Prepaid expense37174313310380509
Other undisclosed current assets444719132
Total current assets:4,1294,9726,1428,0419,92011,446
Noncurrent Assets
Restricted cash and investments101010101010
Other noncurrent assets     1354
Total noncurrent assets:101010102364
TOTAL ASSETS:4,1394,9826,1528,0519,94311,510
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities329182428786918478
Accounts payable27269384657809373
Accrued liabilities5711344129109105
Other undisclosed current liabilities  6712011711112
Total current liabilities:329249548903929590
Noncurrent Liabilities
Other undisclosed noncurrent liabilities    167 
Total noncurrent liabilities:    167 
Total liabilities:329249548904996590
Equity
Equity, attributable to parent3,8104,7335,6047,1478,94710,920
Preferred stock      
Additional paid in capital306,128306,123306,117306,111306,103306,090
Accumulated deficit(302,318)(301,390)(300,513)(298,964)(297,156)(295,170)
Total equity:3,8104,7335,6047,1478,94710,920
TOTAL LIABILITIES AND EQUITY:4,1394,9826,1528,0519,94311,510

Income Statement (P&L) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues     3366
Gross profit:     3366
Operating expenses(908)(866)(1,548)(1,847)(1,955)(3,023)
Operating loss:(908)(866)(1,548)(1,847)(1,952)(2,657)
Nonoperating income (expense)(20)(11)(1)39(34)70
Investment income, nonoperating203041   
Other nonoperating income (expense)(40)(41)(43)(80)(40)(31)
Net loss available to common stockholders, diluted:(928)(877)(1,549)(1,808)(1,986)(2,587)

Comprehensive Income ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net loss:(928)(877)(1,549)(1,808)(1,986)(2,587)
Comprehensive loss, net of tax, attributable to parent:(928)(877)(1,549)(1,808)(1,986)(2,587)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: